Vijayaraj Surendran
Research Subjects
Vijayaraj Surendran has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Narahari Narayan Palei
Amity Institute of Pharmacy, Amity University Uttar Pradesh, Lucknow Campus, India
3 shared publications - Bibhash Chandra Mohanta
Department of Pharmacy, School of Health Science, Central University of South Bihar, Gaya, India
2 shared publications - Murugesan Vanangamudi
Institute of Pharmaceutical Research, GLA University, Mathura, UttarPradesh, 281406, India
2 shared publications - Prathap Madeswaraguptha
Amity Institute of Pharmacy, Amity University, Gwalior, Madhya Pradesh, India
2 shared publications - Biswa Mohan Sahoo
School of Pharmacy and Life Sciences, Centurion University of Technology and Management, Bhubaneswar, Odisha, India
1 shared publication Devalapalli Archana
Sree Vidyanikethan College of Pharmacy, India
1 shared publication
Latest Publications
- 1 July 2025
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 31 (26) , 2105-2116
Formulation, Optimization, and Ex vivo Permeation Study of Ritonavir-loaded Solid Lipid Nanoparticles
Background: Ritonavir (RTV) is an antiviral drug that prevents human immunodeficiency virus (HIV). However, it has low bioavailability, which can be improved with the assistance of Solid Lipid Nanoparticles (SLNs). Objective: The present work aimed to formulate and optimize RTV-loaded SLNs using Box–Behnken design and evaluate the permeability coefficient using ex vivo permeation studies. Methods: RTV-SLNs were prepared using the ultrasonication technique. The SLN formulation was optimized based on particle size, % entrapment efficiency, and % cumulative drug release using response surface methodology resulting from Box-Behnken design. The Fourier-Transform Infrared spectroscopy (FT-IR), Differential Scanning Calorimetry (DSC), and transmission Electron Microscopy (TEM) studies were carried out for the characterization of optimized SLN formulation. Ex vivo permeation studies were also performed using chicken ileum. Results: The optimized RTV-SLNs had a particle size of 270.34 nm, polydispersity index of 0.157, and zeta potential of -25.2 mV. The % entrapment efficiency and % cumulative drug release were found to be 94.33% and 67.13%, respectively. The FT-IR study revealed that SLNs showed no significant interactions between the drug and lipid in the formulation. The % crystalline index of the RTV-loaded SLN formulation was found to be 44.31% compared to the reference value of 100% for lipids. TEM analysis showed spherical nanoparticles that were uniform in shape. The release kinetics data demonstrated the drug release behavior, followed by the Korsmeyer-Peppas model, and suggested that the release from SLNs followed the non-fiction diffusion. The permeability coefficient of optimized SLN formulation was found to be significantly (p < 0.05) more compared to free RTV suspension. The enhancement ratio results suggested that RTV-SLNs permeated significantly (p < 0.05) faster (approximately 3.5 times) as compared to free RTV suspension. Conclusion: The optimized RTV-SLNs could be a promising carrier for improving the oral bioavailability of RTV.
- 1 July 2025
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 31 (26) , 2105-2116
Formulation, Optimization, and Ex vivo Permeation Study of Ritonavir-loaded Solid Lipid Nanoparticles
Background: Ritonavir (RTV) is an antiviral drug that prevents human immunodeficiency virus (HIV). However, it has low bioavailability, which can be improved with the assistance of Solid Lipid Nanoparticles (SLNs). Objective: The present work aimed to formulate and optimize RTV-loaded SLNs using Box–Behnken design and evaluate the permeability coefficient using ex vivo permeation studies. Methods: RTV-SLNs were prepared using the ultrasonication technique. The SLN formulation was optimized based on particle size, % entrapment efficiency, and % cumulative drug release using response surface methodology resulting from Box-Behnken design. The Fourier-Transform Infrared spectroscopy (FT-IR), Differential Scanning Calorimetry (DSC), and transmission Electron Microscopy (TEM) studies were carried out for the characterization of optimized SLN formulation. Ex vivo permeation studies were also performed using chicken ileum. Results: The optimized RTV-SLNs had a particle size of 270.34 nm, polydispersity index of 0.157, and zeta potential of -25.2 mV. The % entrapment efficiency and % cumulative drug release were found to be 94.33% and 67.13%, respectively. The FT-IR study revealed that SLNs showed no significant interactions between the drug and lipid in the formulation. The % crystalline index of the RTV-loaded SLN formulation was found to be 44.31% compared to the reference value of 100% for lipids. TEM analysis showed spherical nanoparticles that were uniform in shape. The release kinetics data demonstrated the drug release behavior, followed by the Korsmeyer-Peppas model, and suggested that the release from SLNs followed the non-fiction diffusion. The permeability coefficient of optimized SLN formulation was found to be significantly (p < 0.05) more compared to free RTV suspension. The enhancement ratio results suggested that RTV-SLNs permeated significantly (p < 0.05) faster (approximately 3.5 times) as compared to free RTV suspension. Conclusion: The optimized RTV-SLNs could be a promising carrier for improving the oral bioavailability of RTV.
- 1 May 2025
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
- Vol. 21 (4) , 443-461
Anticancer Therapy with Proteolysis-targeting Chimeras [PROTACs] Targeting the Tumor-microenvironment: Development, Current State and Prospects
Targeted protein degradation is a rapidly expanding area that offers hope for novel approaches to combat drug resistance. The creation of heterobifunctional proteolysis-targeting chimeras [PROTACs], a new group of pharmaceutical compounds, has made TPD a useful method for completely getting rid of harmful proteins using regular small-molecule inhibitors. A big plus is that PROTACs can target multi-domain proteins that cannot be broken down. This is the case, particularly for proteins lacking a conserved interaction surface for small-molecule ligands SMIs and featuring smooth surfaces. Poor oral bioavailability and pharmacokinetic PK and ADMET absorption, distribution, metabolism, excretion, and toxicity characteristics are among the long-term issues with traditional PROTACs. Their larger size and more complex structure set them apart from other smallmolecule inhibitors, which is why they are so effective. Clinical studies have been conducted on a plethora of PROTAC compounds in the past 20 years, all with the goal of inducing the degradation of targets relevant to cancer. In this article, we closely examine the major developments and recent advancements in PROTAC technology. We seek to summarize and fully assess PROTAC-based targeted protein degradation studies on "undruggable" targets. Discussing their molecular structure, action mechanism, design concepts, development benefits, and obstacles will help to illustrate the significance of developing highly successful PROTAC-based techniques in treating many illnesses, including cancer treatment resistance.
- 1 May 2025
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
- Vol. 21 (4) , 443-461
Anticancer Therapy with Proteolysis-targeting Chimeras [PROTACs] Targeting the Tumor-microenvironment: Development, Current State and Prospects
Targeted protein degradation is a rapidly expanding area that offers hope for novel approaches to combat drug resistance. The creation of heterobifunctional proteolysis-targeting chimeras [PROTACs], a new group of pharmaceutical compounds, has made TPD a useful method for completely getting rid of harmful proteins using regular small-molecule inhibitors. A big plus is that PROTACs can target multi-domain proteins that cannot be broken down. This is the case, particularly for proteins lacking a conserved interaction surface for small-molecule ligands SMIs and featuring smooth surfaces. Poor oral bioavailability and pharmacokinetic PK and ADMET absorption, distribution, metabolism, excretion, and toxicity characteristics are among the long-term issues with traditional PROTACs. Their larger size and more complex structure set them apart from other smallmolecule inhibitors, which is why they are so effective. Clinical studies have been conducted on a plethora of PROTAC compounds in the past 20 years, all with the goal of inducing the degradation of targets relevant to cancer. In this article, we closely examine the major developments and recent advancements in PROTAC technology. We seek to summarize and fully assess PROTAC-based targeted protein degradation studies on "undruggable" targets. Discussing their molecular structure, action mechanism, design concepts, development benefits, and obstacles will help to illustrate the significance of developing highly successful PROTAC-based techniques in treating many illnesses, including cancer treatment resistance.
- 5 February 2023
- Published by Wiley in Separation Science Plus
- Vol. 6 (4)
Estimation of rutin‐loaded chitosan sodium alginate nanoparticles in rat plasma using a chemometrics‐assisted bioanalytical high‐performance liquid chromatography method
Rutin, a flavonoid glycoside is mostly made up of phenolic compounds and is involved in a variety of biological processes. Rutin‐loaded chitosan‐alginate nanoparticles were prepared for enhancing the site specificity and bioavailability. The main focus of the current research work was to develop and validate a simple, accurate, and robust bioanalytical reverse‐phase high‐performance liquid chromatography method using the Design of Experiments principles for the estimation of rutin‐loaded chitosan‐alginate nanoparticles in plasma. A mixture of methanol and phosphate buffer in the ratio of 45:55 v/v was used as the mobile phase. The pH of the mobile phase is adjusted to 3.2 with 80% orthophosphoric acid; the flow rate was optimized to 1.0 ml/min and the ultraviolet absorption wavelength at 254 nm. Critical analytical attributes were screened with Taguchi orthogonal array model design. To develop and analyze a “Design Space,” Box‐Behnken three‐level, three‐factorial design in the design of experiment was employed. Analysis of variance, contour plots, and three‐dimensional surface response plots were used to statistically assess this design, and the model was shown to be statistically significant. The devised approach was validated according to the recommendations of the International Council for Harmonization (Q2 R1). The linearity of the developed method showed excellent in the range of 100 to 900 ng/ml with good regression (R 2 > 0.998), the limit of quantitation (30 ng/ml), and the limit of detection (10 ng/ml). The validation findings of the parameters were examined and found to be within acceptable limits. The study findings stated that the Quality by Design‐driven bioanalytical approach is applicable for the in vivo and in vitro quantification of rutin derived from bulk and rutin‐loaded chitosan‐alginate nanoparticles formation.
- 5 February 2023
- Published by Wiley in Separation Science Plus
- Vol. 6 (4)
Estimation of rutin‐loaded chitosan sodium alginate nanoparticles in rat plasma using a chemometrics‐assisted bioanalytical high‐performance liquid chromatography method
Rutin, a flavonoid glycoside is mostly made up of phenolic compounds and is involved in a variety of biological processes. Rutin‐loaded chitosan‐alginate nanoparticles were prepared for enhancing the site specificity and bioavailability. The main focus of the current research work was to develop and validate a simple, accurate, and robust bioanalytical reverse‐phase high‐performance liquid chromatography method using the Design of Experiments principles for the estimation of rutin‐loaded chitosan‐alginate nanoparticles in plasma. A mixture of methanol and phosphate buffer in the ratio of 45:55 v/v was used as the mobile phase. The pH of the mobile phase is adjusted to 3.2 with 80% orthophosphoric acid; the flow rate was optimized to 1.0 ml/min and the ultraviolet absorption wavelength at 254 nm. Critical analytical attributes were screened with Taguchi orthogonal array model design. To develop and analyze a “Design Space,” Box‐Behnken three‐level, three‐factorial design in the design of experiment was employed. Analysis of variance, contour plots, and three‐dimensional surface response plots were used to statistically assess this design, and the model was shown to be statistically significant. The devised approach was validated according to the recommendations of the International Council for Harmonization (Q2 R1). The linearity of the developed method showed excellent in the range of 100 to 900 ng/ml with good regression (R 2 > 0.998), the limit of quantitation (30 ng/ml), and the limit of detection (10 ng/ml). The validation findings of the parameters were examined and found to be within acceptable limits. The study findings stated that the Quality by Design‐driven bioanalytical approach is applicable for the in vivo and in vitro quantification of rutin derived from bulk and rutin‐loaded chitosan‐alginate nanoparticles formation.
- 1 March 2022
- Published by Bentham Science Publishers Ltd. in Current Drug Delivery
- Vol. 19 (3) , 379-394
Formulation and Characterization of Rutin Loaded Chitosan-alginate Nanoparticles: Antidiabetic and Cytotoxicity Studies
Background: The rutin loaded chitosan-alginate nanoparticles (RCANP) were prepared using an ion gelation method. The optimized RCANP4 formulation composed of rutin: alginate: chitosan with the ratio of 1.24:5:2. The particle size, zeta potential, and entrapment efficiency of RCANP4 formulation were found to be 168.4 ± 11.23 nm, -24.7 ± 1.5 mV, and 91.23 ± 1.1%, respectively. The in vitro drug release of RCANP4 formulation was found to be 88.89 ± 2.9% within 24 h. The Fourier transform infrared spectroscopy (FT-IR) of RCANP4 revealed all characteristic groups of rutin, confirming the successful loading of rutin into the nanoparticles. Methods: Due to rutin entrapment in the chitosan sodium alginate matrix, a broad curve was observed in the Differential Scanning Calorimetry (DSC) study of RCANP4. The RCANP4 was found to be uniform and spherical revealed from Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM). RCANP4 showed 3.54 times more bioavailability than free rutin, resulting in more internalization of rutin in systemic circulation. The results of plasma glucose levels of diabetic rats administered with RCANP4 and rutin were evident that RCANP4 showed effective antidiabetic activity compared to rutin. Results: The results obtained for glucose uptake in HepG2 cells, the RCANP4 caused a significant (P < 0.05) increase in glucose uptake in contrast to rutin. In vitro cytotoxicity results explained that RCANP4 could significantly (P < 0.05) reduce the cells viability rate compared with rutin. It may be due to the internalization of RCANP4 formulations in systemic circulation. Conclusion: The results also showed that RCANP4 could significantly reduce cell viability over 24 h and 48 h compared to free rutin.
- 1 March 2022
- Published by Bentham Science Publishers Ltd. in Current Drug Delivery
- Vol. 19 (3) , 379-394
Formulation and Characterization of Rutin Loaded Chitosan-alginate Nanoparticles: Antidiabetic and Cytotoxicity Studies
Background: The rutin loaded chitosan-alginate nanoparticles (RCANP) were prepared using an ion gelation method. The optimized RCANP4 formulation composed of rutin: alginate: chitosan with the ratio of 1.24:5:2. The particle size, zeta potential, and entrapment efficiency of RCANP4 formulation were found to be 168.4 ± 11.23 nm, -24.7 ± 1.5 mV, and 91.23 ± 1.1%, respectively. The in vitro drug release of RCANP4 formulation was found to be 88.89 ± 2.9% within 24 h. The Fourier transform infrared spectroscopy (FT-IR) of RCANP4 revealed all characteristic groups of rutin, confirming the successful loading of rutin into the nanoparticles. Methods: Due to rutin entrapment in the chitosan sodium alginate matrix, a broad curve was observed in the Differential Scanning Calorimetry (DSC) study of RCANP4. The RCANP4 was found to be uniform and spherical revealed from Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM). RCANP4 showed 3.54 times more bioavailability than free rutin, resulting in more internalization of rutin in systemic circulation. The results of plasma glucose levels of diabetic rats administered with RCANP4 and rutin were evident that RCANP4 showed effective antidiabetic activity compared to rutin. Results: The results obtained for glucose uptake in HepG2 cells, the RCANP4 caused a significant (P < 0.05) increase in glucose uptake in contrast to rutin. In vitro cytotoxicity results explained that RCANP4 could significantly (P < 0.05) reduce the cells viability rate compared with rutin. It may be due to the internalization of RCANP4 formulations in systemic circulation. Conclusion: The results also showed that RCANP4 could significantly reduce cell viability over 24 h and 48 h compared to free rutin.
- Open Access
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 56
Quality by design (Qbd) approach to develop stability indicating HPLC method for estimation of rutin in chitosan-sodium alginate nanoparticles
Rutin is a flavonoid glycoside, mainly consists of phenolic compounds, responsible for many biological activities. The objective of the present study was to develop and validate a precise, simple, robust, rapid and reliable reverse phase high -performance liquid chromatography (RP-HPLC) technique by using Qbd approach for evaluating the rutin in nanoparticles. Central composite design (CCD) was employed for optimizing the experimental conditions of RP-HPLC method. Buffer pH, methanol content in the mobile phase composition, flow rate, and wavelength were selected as independent variables whereas retention time, peak area, and asymmetry factor was selected as dependent variables. The retention time, peak area and asymmetric factor of rutin by using optimized independent variables were found to be 3.75 min, 1014.79 mV, and 1.26 respectively. The limit of detection and limit of quantitation values were found to be 0.005 µg/mL and 0.15 µg/mL respectively. For confirming linearity, accuracy, precision, and robustness, the optimized assay condition was validated as per ICH guidelines. The proposed method, which was optimized by QbD approach was found to be a suitable method for analyzing the rutin in chitosan-sodium alginate nanoparticles.
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 56
Open AccessQuality by design (Qbd) approach to develop stability indicating HPLC method for estimation of rutin in chitosan-sodium alginate nanoparticles
Rutin is a flavonoid glycoside, mainly consists of phenolic compounds, responsible for many biological activities. The objective of the present study was to develop and validate a precise, simple, robust, rapid and reliable reverse phase high -performance liquid chromatography (RP-HPLC) technique by using Qbd approach for evaluating the rutin in nanoparticles. Central composite design (CCD) was employed for optimizing the experimental conditions of RP-HPLC method. Buffer pH, methanol content in the mobile phase composition, flow rate, and wavelength were selected as independent variables whereas retention time, peak area, and asymmetry factor was selected as dependent variables. The retention time, peak area and asymmetric factor of rutin by using optimized independent variables were found to be 3.75 min, 1014.79 mV, and 1.26 respectively. The limit of detection and limit of quantitation values were found to be 0.005 µg/mL and 0.15 µg/mL respectively. For confirming linearity, accuracy, precision, and robustness, the optimized assay condition was validated as per ICH guidelines. The proposed method, which was optimized by QbD approach was found to be a suitable method for analyzing the rutin in chitosan-sodium alginate nanoparticles.
- 30 August 2019
- Published by Bentham Science Publishers Ltd. in Current Nanomaterials
- Vol. 4 (2) , 84-100
Lipid Based Nanoparticles: Current Strategies for Brain Tumor Targeting
Brain tumors arise from an uncontrolled proliferation of neural tissue cells or supportive glial tissue cells within the brain. The diagnosis and therapy of brain tumor is an extremely challenging task. Moreover, absence of early stage symptoms and consequently delays in diagnosis and therapy worsen its severity. Though in the present days, chemotherapeutic approach is the most common therapeutic approach; still it is linked with several precincts. The blood-brain barrier (BBB) is the main hurdle in delivering most of the chemotherapeutic agents as well as imaging agent that leads to insufficient accumulation of therapeutic / imaging agents at tumor site, and prevents adequate destruction of malignant cells. Recently, lipid based nanoparticles are gaining much more interest and are preferred over polymeric nanoparticles owing to their biodegradability, non-toxicity, excellent tumortargeting ability and ease of surface modification. Certain receptors are over expressed in brain tumor cells which confer an opportunity to the researchers for delivering the chemotherapeutic as well as imaging agent particularly to the tumor cells through the surface modification approach of nanoparticles. Ligands like proteins/peptides, carbohydrates, aptamers, antibodies, and antibody fragments are generally conjugated to the surface of the nanoparticles that bind specifically to an over expressed target on the brain tumor cell surface. In the present review, we discuss the diagnostic and therapeutic application of various types of lipid based nanoparticles such as liposomes, niosomes, solid lipid nanoparticles, nanostructured lipid carrier, lipid nanocapsule, and lipid polymer hybrid nanocarriers along with their various surface modified forms for targeting brain tumor.
- 30 August 2019
- Published by Bentham Science Publishers Ltd. in Current Nanomaterials
- Vol. 4 (2) , 84-100
Lipid Based Nanoparticles: Current Strategies for Brain Tumor Targeting
Brain tumors arise from an uncontrolled proliferation of neural tissue cells or supportive glial tissue cells within the brain. The diagnosis and therapy of brain tumor is an extremely challenging task. Moreover, absence of early stage symptoms and consequently delays in diagnosis and therapy worsen its severity. Though in the present days, chemotherapeutic approach is the most common therapeutic approach; still it is linked with several precincts. The blood-brain barrier (BBB) is the main hurdle in delivering most of the chemotherapeutic agents as well as imaging agent that leads to insufficient accumulation of therapeutic / imaging agents at tumor site, and prevents adequate destruction of malignant cells. Recently, lipid based nanoparticles are gaining much more interest and are preferred over polymeric nanoparticles owing to their biodegradability, non-toxicity, excellent tumortargeting ability and ease of surface modification. Certain receptors are over expressed in brain tumor cells which confer an opportunity to the researchers for delivering the chemotherapeutic as well as imaging agent particularly to the tumor cells through the surface modification approach of nanoparticles. Ligands like proteins/peptides, carbohydrates, aptamers, antibodies, and antibody fragments are generally conjugated to the surface of the nanoparticles that bind specifically to an over expressed target on the brain tumor cell surface. In the present review, we discuss the diagnostic and therapeutic application of various types of lipid based nanoparticles such as liposomes, niosomes, solid lipid nanoparticles, nanostructured lipid carrier, lipid nanocapsule, and lipid polymer hybrid nanocarriers along with their various surface modified forms for targeting brain tumor.